Evidence map›Paper›PMID 24962607›Full record

Trial reportSchizophrenia bulletin2015

A double-blind randomized controlled trial of oxytocin nasal spray and social cognition training for young people with early psychosis.

Cristina Cacciotti-Saija, Robyn Langdon, Philip B Ward, Ian B Hickie, Elizabeth M Scott, Sharon L Naismith, Loretta Moore, Gail A Alvares, Marie Antoinette Redoblado Hodge, Adam J Guastella

Open access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Schizophrenia bulletin, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed, 8 pooled it
18.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 8 syntheses or guidelines pooled it, 117 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Psychological interventions for psychosis in adolescents.The Cochrane database of systematic reviews · 2020
    Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Cristina Cacciotti-SaijaBrain & Mind Research Institute, University of Sydney, Sydney, Australia;
Robyn LangdonARC Centre of Excellence in Cognition and its Disorders (CCD), Macquarie University, Sydney, Australia;
Philip B WardSchool of Psychiatry, University of New South Wales, Sydney, Australia;
Ian B HickieBrain & Mind Research Institute, University of Sydney, Sydney, Australia;
Elizabeth M ScottBrain & Mind Research Institute, University of Sydney, Sydney, Australia;
Sharon L NaismithBrain & Mind Research Institute, University of Sydney, Sydney, Australia;
Loretta MooreBrain & Mind Research Institute, University of Sydney, Sydney, Australia;
Gail A AlvaresBrain & Mind Research Institute, University of Sydney, Sydney, Australia;
Marie Antoinette Redoblado HodgeChild Development Unit, The Children's Hospital at Westmead, Sydney, Australia.
Adam J GuastellaBrain & Mind Research Institute, University of Sydney, Sydney, Australia; adam.guastella@sydney.edu.au.
MIND Research Institute · USUniversity of Sydney · AUChildren's Hospital at Westmead · AUMacquarie University · AUUNSW Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Social-cognitive deficits contribute to poor functional outcomes in early psychosis; however, no effective pharmacological treatments exist for these problems. This study was the first to investigate the efficacy of an extended treatment of oxytocin nasal spray combined with social cognition training (SCT) to improve social cognition, clinical symptoms, and social functioning in early psychosis. In a double-blind, randomized, placebo-controlled, between-subjects trial, 52 individuals (aged 16-35 years) diagnosed with an early psychosis schizophrenia-spectrum illness were recruited. Participants received oxytocin (24 International Units) or placebo nasal spray twice-daily for 6 weeks, combined with group SCT (2 × 1 hour weekly sessions for 6 weeks). An additional dose of oxytocin was administered before each weekly session. Assessments were conducted at baseline, post-treatment, and at 3-month follow-up. Primary outcomes included the Reading the Mind in the Eyes Test, the Scale for the Assessment of Positive and Negative Symptoms, and the Social Functioning Scale. Secondary outcomes included self-report and behavioral assessments of social cognition, symptom severity, and social functioning. Results showed that on all primary and secondary outcomes, there was no benefit of oxytocin nasal spray treatment in comparison to placebo. Exploratory post hoc analysis suggested that increased use of nasal spray was, however, associated with reductions in negative symptoms in the oxytocin condition only. This study represents the first evaluation of oxytocin treatment for early psychosis. Although results suggest no benefit of oxytocin treatment, results also highlight an urgent need to consider nasal spray delivery and dose-related variables for future clinical trials.

Indexed as

Social PerceptionAdolescentAdultCognitive Behavioral TherapyCombined Modality TherapyDouble-Blind MethodFemaleFollow-Up StudiesHumansMaleNasal SpraysOxytocinPsychotic DisordersTreatment OutcomeYoung AdultNasal SpraysOxytocinemotion recognitionneuropeptidesschizophreniasocial behavior

Identifiers

PMID24962607
PMCPMC4332939
OpenAlexW2126398688

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.